View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, Oct. 9 (HealthDay News) -- Immunosuppressed patients, particularly solid-organ transplant recipients and lymphoma patients, have about a two-fold or higher risk of developing melanoma, according to research published in the October issue of the Mayo Clinic Proceedings.
Agnieszka W. Kubica and Jerry D. Brewer, M.D., of the Mayo Medical School College of Medicine in Rochester, Minn., performed a comprehensive review to summarize the literature on the role of immunosuppression in melanoma and discuss several immunocompromised patient populations in detail, including solid-organ transplant recipients, those with lymphoproliferative disease, those with iatrogenic immunosuppression, and patients with HIV infection/AIDS.
Upon reviewing studies with large numbers of patients and population-based national and international epidemiologic studies, the researchers found an increase in the incidence of melanoma among immunosuppressed patients. The largest studies showed that transplant recipients and lymphoma patients had an approximately two-fold or higher risk of developing melanoma and a higher risk of dying from melanoma. Patients with chronic lymphocytic leukemia were 2.8-fold more likely to die from metastatic melanoma.
"How you catch melanoma earlier is to be very aware of your skin," Brewer said in a statement. "These patients with immunosuppression should be looking themselves over head-to-toe once a month, they should be seeing a dermatologist once or twice a year, and if they have a lot of other risk factors, maybe more often than that."
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top